Inhibitory effect of T-614 on tumor necrosis factor-α induced cytokine production and nuclear factor-κB activation in cultured human synovial cells

Journal of Rheumatology

Volumn 28, Issue 12, 2001, Pages 2591-2596

  Kohno, M ^a   Aikawa, Y ^a   Tsubouchi, Y ^a   Hashiramoto, A ^a   Yamada, R ^a   Kawahito, Y ^a   Inoue, K I ^a   Kusaka, Y ^a   Kondo, M ^a   Sano, H ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chemokine; Nuclear factor B; Rheumatoid arthritis; Synovial cells; T 614; Tumor necrosis factor

Indexed keywords

CHEMOKINE; CYTOKINE; IGURATIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANTIRHEUMATIC AGENTS; BENZOPYRANS; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; SYNAPTOTAGMIN I; SYNAPTOTAGMINS; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035204246     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Cytokine expression in rheumatoid arthritis
2. Rheumatoid arthritis: Pathophysiology and implications for therapy
3. Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and fibroblasts
4. Production of monocyte chemotactic protein-1 in human type B synoviocytes. Synergistic effect of tumor necrosis factor α and interferon-γ
5. Randomized double blind comparison of a chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
6. Activation of HIV gene expression during monocyte differentiation by induction of NF-κB
7. Function and activation of NF-κB in the immune system
8. Re1/NF-κB/IκB story
9. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor
10. Cooperative interaction of nuclear factor-κB- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines
11. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene
12. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. Inhibitory effect on the production of interleukin-1 and interleukin-6
13. Pharmacological studies on T-614, a novel antiinflammatory agent: Effect on type II collagen-induced arthritis in DBA/IJ mice and spontaneous arthritis in MRL/I mice
14. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis
15. C-myc antisense oligodeoxynucleotides can induce apoptosis and downregulates Fas expression in rheumatoid synoviocytes
16. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
17. Single-step method of RNA isolation by acidic guanidium thiocyanate-phenol-chloroform extraction
18. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor
19. Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer
20. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis
21. Auranofin inhibits interleukin-1β-induced transcript of cyclooxygenase-2 on cultured human synoviocytes
22. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino -6-phenoxy-4H-1-benzopyran-4-one. Antiinflammatory, analgesic and other related properties
23. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. Effect on the arachidonic acid cascades
24. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. The involvement of bradykinin in its analgesic actions
25. Immunopharmacological profile of T-614, a new anti-rheumatic agent
26. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells
27. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1
28. Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in human gastric cancer cell line through acting concurrently on AP-1 and NF-κB-like binding sites of the interleukin 8 gene
29. A promoter recruitment mechanism for tumor necrosis factor-alpha-induced interleukin-8 transcription in type II pulmonary epithelial cells. Dependence on nuclear abundance of Re1 A, NF-κB1, and c-Re1 transcription factors
30. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-κB and AP-1
31. Activation of nuclear factor-kappa B correlates with MCP-1 expression by human mesangial cells
32. Nuclear factor-κB in rheumatoid synovium. Localization of p50 and p65
33. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α
34. Synovial fluid concentration of five different cytokines in rheumatic diseases
35. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
36. Structure of the human cyclooxygenase-2 gene
37. Involvement of nuclear factor κB in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes
38. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 in cultured fibroblasts